Literature DB >> 26833215

Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.

Krystallenia I Alexandraki1, Ashley B Grossman2.   

Abstract

Severe Cushing's syndrome presents an acute emergency and is defined by massively elevated random serum cortisol [more than 36 μg/dL (1000 nmol/L)] at any time or a 24-h urinary free cortisol more than fourfold the upper limit of normal and/or severe hypokalaemia (<3.0 mmol/L), along with the recent onset of one or more of the following: sepsis, opportunistic infection, intractable hypokalaemia, uncontrolled hypertension, heart failure, gastrointestinal haemorrhage, glucocorticoid-induced acute psychosis, progressive debilitating myopathy, thromboembolism or uncontrolled hyperglycaemia and ketocacidosis. Treatment focuses on the management of the severe metabolic disturbances followed by rapid resolution of the hypercortisolaemia, and subsequent confirmation of the cause. Emergency lowering of the elevated serum cortisol is most rapidly achieved with oral metyrapone and/or ketoconazole; if parenteral therapy is required then intravenous etomidate is rapidly effective in almost all cases, but all measures require careful supervision. The optimal order and combination of drugs to treat severe hypercortisolaemia-mostly in the context of ectopic ACTH-secreting syndrome, adrenocortical carcinoma or an ACTH-secreting pituitary adenoma (mainly macroadenomas)-is not yet established. Combination therapy may be useful not only to rapidly control cortisol excess but also to lower individual drug dosages and consequently the possibility of adverse effects. If medical treatments fail, bilateral adrenalectomy should be performed in the shortest possible time span to prevent the debilitating complications of uncontrolled hypercortisolaemia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26833215     DOI: 10.1007/s40265-016-0539-6

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  86 in total

1.  Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.

Authors:  Phillip J Monaghan; Laura J Owen; Peter J Trainer; Georg Brabant; Brian G Keevil; Denise Darby
Journal:  Ann Clin Biochem       Date:  2011-08-03       Impact factor: 2.057

Review 2.  Management of endocrine disease: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis.

Authors:  Femke M van Haalen; Leonie H A Broersen; Jens O Jorgensen; Alberto M Pereira; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2015-04       Impact factor: 6.664

3.  Successful control of Cushing's disease in the elderly with long term metyrapone.

Authors:  J Donckier; J M Burrin; I D Ramsay; G F Joplin
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

4.  Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.

Authors:  Victoria Delgado; Nienke R Biermasz; Sjoerd W van Thiel; See H Ewe; Nina Ajmone Marsan; Eduard R Holman; Richard A Feelders; Johannes W A Smit; Jeroen J Bax; Alberto M Pereira
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

5.  Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release.

Authors:  M G Caron; M Beaulieu; V Raymond; B Gagné; J Drouin; R J Lefkowitz; F Labrie
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

6.  Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

Authors:  H M Schulte; G Benker; D Reinwein; W G Sippell; B Allolio
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

7.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

8.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Authors:  Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

9.  Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis.

Authors:  W M Drake; L A Perry; C J Hinds; D G Lowe; R H Reznek; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

Review 10.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

View more
  8 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 2.  Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.

Authors:  Lukasz Dzialach; Joanna Sobolewska; Wioleta Respondek; Agnieszka Wojciechowska-Luzniak; Przemyslaw Witek
Journal:  Hormones (Athens)       Date:  2022-09-21       Impact factor: 3.419

Review 3.  Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature.

Authors:  M S Elston; V B Crawford; M Swarbrick; M S Dray; M Head; J V Conaglen
Journal:  Endocr Connect       Date:  2017-06-05       Impact factor: 3.335

Review 4.  Update on medical treatment for Cushing's disease.

Authors:  Daniel Cuevas-Ramos; Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Clin Diabetes Endocrinol       Date:  2016-09-13

5.  Small cell lung cancer starting with diabetes mellitus: Two case reports and literature review.

Authors:  Tong Zhou; Yao Wang; Xue Zhao; Yang Liu; Ying-Xuan Wang; Xiao-Kun Gang; Gui-Xia Wang
Journal:  World J Clin Cases       Date:  2019-05-26       Impact factor: 1.337

6.  TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.

Authors:  Jie Ren; Changwei Gu; Yong Yang; Jun Xue; Yuhao Sun; Fangfang Jian; Dongjiang Chen; Liuguan Bian; Qingfang Sun
Journal:  J Cell Mol Med       Date:  2019-04-23       Impact factor: 5.310

7.  Using Etomidate in a Two-month-old Infant with Cushing Syndrome due to Adrenocortical Carcinoma

Authors:  Ahreum Kwon; Yongha Choi; Jo Won Jung; Junghwan Suh; Ho-Seong Kim
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-11-30

8.  Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.

Authors:  Agnieszka Łebek-Szatańska; Karolina M Nowak; Wojciech Zgliczyński; Elżbieta Baum; Agnieszka Żyłka; Lucyna Papierska
Journal:  Ther Adv Endocrinol Metab       Date:  2019-02-08       Impact factor: 3.565

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.